Eikon Therapeutics Jumps Ahead of Biotech Peers
Eikon Therapeutics shares rose 5.1% to $9.91 late Thursday morning, still about 45% below the $18 IPO price from February. The company completed enrollment for its Phase 2 lung cancer trial, reporting a 63.1% objective response rate. Eikon ended Q1 with $596 million in cash but posted an $83 million loss. Analyst price targets averaged $24.80, with most maintaining a “Buy” rating.